FDA
-
-
-
-
-
-
-
Theravance Biopharma drug trial fails, company cuts costs 60%
-
-
-
-
-
-
-
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
-
-
-
-
-
-
-
Theravance Biopharma completes enrollment in phase 3 drug study
-
-
-
-
-
-
-
Theravance Biopharma (TBPH) Sells Remaining Royalty Interest in Trelegy Ellipta to GSK (GSK) for $225M
-
-
-
-
-
-
-
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
-
-
-
-
-
-
-
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
-
-
-
-
-
-
-
Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
-
325,726 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

